The Tuberculosis Drugs Market is Forecast to Decline Until 2016 The global Tuberculosis (TB) drugs market was worth $99m in 2009. The market is expected to decline by 2.8% during the next seven years to reach $80m by 2016. The TB drugs market has been well served by antimycobacterial agents and antibiotics since the 1960s. The cure rates have been improved with the conventional DOTS (Directly Observed Therapy). Multi-Drug Resistant Tuberculosis (MDR-TB) has been a consequence of patient non-compliance and the long duration of therapy. Companies seem to be actively developing products for the prophylaxis and cure of TB with lesser treatment duration. The two not-for-profit organizations, TB Alliance and the Aeras Global TB Vaccine Foundation, have partnered with pharmaceutical players in order to address the burden of TB in developed and developing nations. With the success of the ongoing clinical studies, the market is expected to witness a breakthrough in TB control and treatment. The vaccines’ primary focus would be to inhibit the infection in the first place. The global TB drugs market is heading towards a phase of decline as no launches are expected until 2016. For more information please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Tuberculosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Competition in the Tuberculosis Drugs Market is Weak GlobalData found the current competition in the TB market to be weak. Though the market is well served by the treatment and cure options for TB, all of the available therapies are generics. The treatment regimens, DOTS and DOTS-PLUS, have been approved by the World Health Organization (WHO). The cure rates with existing therapies have been observed to be more than 85%. TB treatments are provided through Primary Healthcare Centers (PHC) under the subsidized prices in the developed and developing nations. The future landscape does not provide much hope as no launches are expected until 2016. However, the market is expected to witness a breakthrough for TB control and cure. The competition is anticipated to be low in light of no expected launches in the TB therapeutics market.
Lack of Improved Diagnostic Capacity to Uncover MDR-TB GlobalData found that there is a lack of diagnostic capacity for the detection of TB, especially MDR-TB, another roadblock which would prevent the growth of TB drugs market. This is deemed to be a crucial barrier in preventing an effective response to the challenges of the drug-resistant TB. Though recent and ongoing developments in drug therapies offer great promise for treating and curing TB, the new medicines have limited value, especially in places where TB is unrestrained and violent. This is because the principal diagnostic tools used for determining TB, such as microscopic examination of stained sputum and chest X-ray, do not offer accuracy in determining all forms of TB. The detection rates have been observed to be very low in MDR-TB patients when compared to primary TB sufferers. In addition, many poor and vulnerable people lack access to even these basic diagnostic tools, which makes it too late to detect, and this consequently enables them to transmit the disease to others. The limited treatment options leave behind a substantial segment of unmet need. For more information please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Tuberculosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare MDR-TB, A Consequence of Non-compliance and Lengthy Treatment Duration Poor compliance with TB treatment has been cited as one of the major obstacles which have led to development of MDR-TB and chronic TB. TB is unique in that even after clinical recovery, a long period of treatment has to be given to prevent relapses. Most patients tend to stop taking treatment when they feel better due to a lack of knowledge, the fear of side effects or other reasons. Poor compliance leads to relapses, MDR-TB and the occurrence of chronic cases which are very difficult to treat and require prolonged hospitalization in specialized centers.
Strong Pipeline to Alter the Course of Tuberculosis in the Near Future The pipeline of TB is strong. Unmet needs existing in the market are low, and those which do exist are mainly because of low patient compliance, the side-effects associated with the current therapies and the duration of therapy. The reasons for poor interest in bringing novel drugs into the market over the years have been the success of the existing drug classes in treating the disease and increased response rates, along with the prevention of drug resistance in TB patients. The main reasons for the revitalization of the market are the increased demand for therapeutic and preventive treatments. GlobalData's report, “Tuberculosis - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global tuberculosis market. The report identifies the key trends shaping and driving the global tuberculosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. For more information please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Tuberculosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Or visit our report store: http://www.globaldata.com/reportstore Contact Information: Rajesh Gunnam email@example.com +914066166782